Study finds micro-LED mask boosts elasticity 12.8% alongside PN injections
For 33 participants, the experiment came down to a split face: PN injections—the study's skin-rejuvenation treatment—were given across the entire face, while a flexible micro-LED mask was applied to one side for eight weeks. On the treated side, deep skin elasticity improved 12.8%, versus 3.1% where injections were used alone.
The hardware is designed around distance. Conventional LED masks use rigid structures and point-emitting LEDs that must sit away from the skin to spread light, creating gaps and optical loss. KAIST's mask combines a dense surface-emitting micro-LED layer with a light-diffusing layer and a three-dimensional elastic scaffold whose supports move independently along facial contours.
That scaffold increased skin contact from 46.9% to 78.1%, reduced the light-source-to-skin distance to 1.8 mm, and delivered 93.83% light uniformity across eight facial measurement sites. The approach follows a 2024 Advanced Materials study in which Professor Keon Jae Lee's team clinically reported up to 340% greater improvement in deep skin elasticity than conventional LED masks.
The result was not limited to elasticity. The micro-LED-treated side improved across all five reported skin-brightening measures, including brightness, tone uniformity, exfoliation, melasma count and melasma area. Human-derived skin tissue treated with micro-LEDs also showed reduced expression of MITF and TYR, markers linked to melanin production. Skin-barrier recovery was faster and post-procedure redness was reduced more strongly; the researchers suggest the effect may involve mitochondrial ATP production and regenerative responses.
Concretely, the mask points to a home treatment that could extend an in-clinic injection's effect into brightening and post-procedure recovery, rather than replacing the injection. Its limits are equally clear: every participant received PN injections, the comparison was between sides of the same face, and the study lasted eight weeks. A related product from the KAIST–AMOREPACIFIC collaboration is scheduled for Japan in Q4 2026 and the U.S. in Q1 2027.
Comments
Loading the thread…
Sign in to leave a comment. Sign in